Figure 1.
JZL184 effects in leukocyte migration into the lungs.
(A) Total and differential leukocyte count in the bronchoalveolar lavage fluid, (B) Total and differential leukocyte count in the blood and (C) Percentage of granulocytes in the bone marrow. Data are presented as mean ± S.D., n=5-9 mice/group. *p<0.05, in relation to C2 group and #p<0.05 in relation to C1 group. One-way ANOVA and Tukey-Kramer tests.
Figure 2.
JZL184 effects on lung architecture in LPS-induced lung damage.
(A) Non inflamed control; (B) Inflamed control 6 hours, (C) Inflamed control 24 hours and (D) Inflamed control 48 hours after LPS intranasal instillation; (E) JZL184 treated animals 6 hours, (F) JZL184 treated animals 24 hours and (G) JZL184 treated animals 48 hours after LPS intranasal instillation. Sections from the left lung lobe were stained with hematoxylin and eosin. Representative pictures are shown for each experimental group (magnification = 200X).
Figure 3.
JZL184 effects LPS-induced lung damage.
(A) Alveolar wall thickness and (B) ALI score. Data are presented as mean ± S.D., n=5-6 mice/group. *p<0.05, in relation to C2 group. (A) One-way ANOVA and Tukey-Kramer tests; (B) Mann Whitney U test for two group comparison.
Figure 4.
JZL184 effects in adhesion molecules expression in LPS-induced ALI.
(A) β2-integrin and (B) L-selectin in the blood 6 hours after LPS-induced ALI. (C) β2-integrin in the bronchoalveolar lavage fluid 48 hours after LPS-induced ALI. Data are mean ± S.D., n=5-9 mice/group. *p<0.05 in relation to C2 group. Mann Whitney U test for two group comparison.
Figure 5.
JZL184 effects on albumin concentration in the bronchoalveolar lavage fluid.
Data are mean ± S.D., n=5-8 mice/group. *p<0.05 in relation to C2 group. Mann Whitney U test for two groups comparisons. Data are normalized to protein of control.
Figure 6.
JZL184 effects in cytokines/chemokines concentration in the bronchoalveolar lavage fluid.
(A) TNF-α, (B) IL-6 and (C) MCP-1. Data are mean ± S.D., n=5-8 mice/group. *p<0.05 in relation to C2 group. Mann Whitney U test for two groups comparisons.
Figure 7.
CB1 and CB2 receptors participation in leukocyte migration into the lungs.
(A) Leukocyte count in the bronchoalveolar lavage fluid, (B) Leukocyte count in the blood, (C) neutrophils count in the blood and (D) the percentage of granulocytes in the bone marrow. Data are mean ± S.D., n=5-8 mice/group. * and **p<0.05. One-way ANOVA and Tukey-Kramer tests.
Figure 8.
CB1 and CB2 receptors participation in LPS-induced lung damage.
(A) Alveolar wall thickness and (B) ALI score. Data are presented as mean ± S.D., n=5-8 mice/group. * and **p<0.05. (A) One-way ANOVA and Tukey-Kramer tests; (B) Kruskal-Wallis and Dunn´s tests for multiples comparisons.
Figure 9.
CB1 and CB2 receptors participation in adhesion molecules expression in LPS-induced ALI.
(A) β2-integrin in the blood 6 hours after LPS-induced ALI, (B) L-selectin in the blood 6 hours after LPS-induced ALI and (C) β2-integrin in the bronchoalveolar lavage fluid 48 hours after LPS-induced ALI. Data are mean ± S.D., n=5-8 mice/group. * and **p<0.05. Kruskal-Wallis and Dunn´s tests for multiples comparisons.
Figure 10.
CB1 and CB2 receptors participation on albumin concentration in the bronchoalveolar lavage fluid.
Data are mean ± S.D., n=5-8 mice/group. * and **p<0.05. Kruskal-Wallis and Dunn´s tests for multiples comparisons.
Figure 11.
CB1 and CB2 receptors participation in cytokine/chemokine concentrations in the bronchoalveolar lavage fluid.
(A) TNF-α, (B) IL-6 and (C) MCP-1. Data are mean ± S.D., n=5-8 mice/group. * and **p<0.05. Kruskal-Wallis and Dunn´s tests for multiples comparisons.